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Abstract
Background: Age at onset in Parkinson disease (PD) is a highly heritable quantitative trait for which a significant
genetic influence is supported by multiple segregation analyses. Because genes associated with onset age may
represent invaluable therapeutic targets to delay the disease, we sought to identify such genetic modifiers using a
genomewide association study in familial PD. There have been previous genomewide association studies (GWAS)
to identify genes influencing PD susceptibility, but this is the first to identify genes contributing to the variation in
onset age.
Methods: Initial analyses were performed using genotypes generated with the Illumina HumanCNV370Duo array
in a sample of 857 unrelated, familial PD cases. Subsequently, a meta-analysis of imputed SNPs was performed
combining the familial PD data with that from a previous GWAS of 440 idiopathic PD cases. The SNPs from the
meta-analysis with the lowest p-values and consistency in the direction of effect for onset age were then
genotyped in a replication sample of 747 idiopathic PD cases from the Parkinson Institute Biobank of Milan, Italy.
Results: Meta-analysis across the three studies detected consistent association (p < 1 × 10-5) with five SNPs,
none of which reached genomewide significance. On chromosome 11, the SNP with the lowest p-value
(rs10767971; p = 5.4 × 10-7) lies between the genes QSER1 and PRRG4. Near the PARK3 linkage region on
chromosome 2p13, association was observed with a SNP (rs7577851; p = 8.7 × 10-6) which lies in an intron of
the AAK1 gene. This gene is closely related to GAK, identified as a possible PD susceptibility gene in the GWAS of
the familial PD cases.
Conclusion: Taken together, these results suggest an influence of genes involved in endocytosis and lysosomal
sorting in PD pathogenesis.
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Parkinson disease (PD), the second most common neuro-
degenerative disorder, is characterized by debilitating
symptoms of tremor, rigidity, and bradykinesia, usually
occurring late in life. PD incidence increases with age from
1.7/10,000 person-years between ages 50 to 59 to 9.3/
10,000 person-years between ages 70 to 79 and has a prev-
alence of approximately 1.8% among people over the age
of 65 [1]. While the average age of onset of PD is approx-
imately 60 years, there is wide variation, with some indi-
viduals having onset before age 20 and others not until
after age 90 [2,3].
Five monogenic forms of PD have been identified and
characterized by mode of transmission, onset age and pro-
tein affected by mutation. These include α-synuclein
(SNCA or PARK1) [4], parkin (PARK2) [5], PTEN-induced
putative kinase 1 (PINK1 or PARK6) [6], DJ-1 (PARK7)
[7], and leucine-rich repeat kinase 2 (LRRK2 or PARK8)
[8]. Onset for PARK1 is younger than that seen for idio-
pathic PD [4]. PARK2 (parkin) is a recessive form with
young onset, commonly before age 40. Heterozygous
mutations in parkin are also associated with earlier onset
of PD, typically in the early to mid sixth decade [9,10]. By
contrast, PD associated with LRRK2 mutations presents an
onset distribution very similar to that seen in idiopathic
PD, as well as clear age-dependent penetrance [11-13].
Onset of PD has been shown to be correlated between sib-
lings with PD [14] suggesting that genetic modifiers influ-
ence onset age. Segregation analyses in three independent
studies showed evidence of a genetic effect influencing age
of onset of PD [15-17]. Notably, all three of these segrega-
tion analyses showed stronger evidence for the presence of
"major genes" influencing onset age or penetrance, than
for genes influencing susceptibility. Furthermore, age is
one of the strongest risk factors for PD, suggesting that age
related penetrance is strongly associated with disease
expression. By identifying genes related to onset age, it
may be possible to identify pathogenic mechanisms and
therapeutic targets capable of delaying onset of disease
symptoms. Effectively postponing disease onset will
reduce disease prevalence and ease the burden of PD in
our aging population.
All prior PD genome wide association studies (GWAS)
have focused exclusively on the detection of susceptibility
genes and none has investigated association to genes
influencing onset age [18-20]. In this study, we describe
the first GWAS of onset age. This GWAS included 857 PD
cases with a positive family history of PD. In addition, we
performed a second GWAS with onset age as the pheno-
type using publicly available data from 440 randomly
ascertained PD cases [19]. We conducted a meta-analysis
of the two studies comprising approximately 2 million
SNPs imputed using HapMap data. Finally, a replication
study of the top findings from the meta-analysis was per-
formed in an independent sample of 747 randomly ascer-
tained PD cases from Milan, Italy.
Methods
PD Cases
One PD case (n = 935) from each family recruited from
two ongoing studies of familial PD, the GenePD study
and the PROGENI study, was selected for the GWAS. Both
studies recruited families consisting of at least two mem-
bers meeting diagnostic criteria for PD. PD cases under-
went a uniform neurological evaluation that employed
PD diagnostic criteria based on a modified version of the
United Kingdom PD Society Brain Bank Criteria [21].
Detailed descriptions of the inclusion and exclusion crite-
ria are described elsewhere for the PROGENI [22] and
GenePD [14] studies. The analyzed sample was exclu-
sively white, non-Hispanic.
No subject known to have a disease-producing mutation
was included in this analysis. All cases were known to be
negative for the LRRK2 G2019S mutation, and many, but
not all, were also screened for PARK1(SNCA)(N screened
= 702), PARK2 (parkin)(N = 593), PARK7 (DJ1)(N = 328),
and NR4A2 (N = 550) [9,10,12,23-27]. PD onset age was
determined by interview and reflected the age of first
symptom of PD, which commonly preceded age of physi-
cian diagnosis. The reliability of ascertaining age of onset
though interview compared to medical records has been
estimated as 0.94 [28].
In addition, control samples (n = 895) obtained from the
NINDS Human Genetics Resource Center DNA and Cell
Line Repository (Camden, NJ) were intermixed on the
same plates as the cases when genotyped. All selected con-
trol samples were reported to be white, non-Hispanic.
While not used in the analysis of onset age of PD, these
samples were used for SNP and sample quality assessment
and genotype imputation as described below.
Appropriate written informed consent was obtained for
all samples included in this study.
Microarray Genotyping and Quality Assessment
Genotyping was performed by the Center for Inherited
Disease Research (CIDR) using the Illumina
HumanCNV370 version1_C BeadChips (Illumina, San
Diego, CA, USA) and the Illumina Infinium II assay pro-
tocol [29]. As previously described [20], 78 cases and 28
controls were removed due to a low genotype call rate
(<98% of SNPs), cryptic relatives in the sample, or popu-
lation stratification. The final sample included 857 PD
cases (all derived from whole blood) and 867 control
DNA samples (all derived from lymphoblastoid cellPage 2 of 14
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from allele cluster definitions for each SNP as determined
by the Illumina BeadStudio Genotyping Module version
3.1.14 and the combined intensity data from 96% of
study samples as previously described [20]. Genotype
calls with a quality score (Gencall value) of 0.25 or higher
were considered acceptable. Blind duplicate reproducibil-
ity was 99.98%. Although we performed additional SNP
filtering described below, the CIDR released dataset con-
tained 344,301 SNPs and is available on dbGaP (http://
www.ncbi.nlm.nih.gov/sites/entrez?db=gap; Accession
number: phs000126.v1.p1).
SNPs were removed if: 1) the call rate of the SNPs was
lower than 98% (n = 7,764), 2) the minor allele frequency
was less than 0.01 in the combined case and control data-
set (n = 7,667), 3) there were differential rates of missing
genotypes in the cases and controls (n = 75) or males and
females (n = 271), or 4) significant deviation from Hardy
Weinberg equilibrium was observed in the control sample
(n = 906). Many markers failed multiple tests. The final
dataset consisted of 328,189 SNPs that passed all quality
control measures (94.6% of all attempted SNPs).
Mayo-Perlegen LEAPS sample
Publicly available SNP genotype data for 443 PD cases
was accessed from dbGaP for the GWAS "Mayo-Perlegen
LEAPS (Linked Efforts to Accelerate Parkinson's Solu-
tions) Collaboration" (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=gap; Accession number:
phs000048.v1.p1; [19]. This data set included genotyping
for the 198,345 SNPs meeting the quality control stand-
ards described by Maraganore et al. [19]. We examined
these data for population stratification and for cryptic
relatedness. While no population outliers were observed,
three individuals were removed due to apparent second-
degree relationships identified during our review of the
data, leaving a sample of 440 PD cases included in these
analyses. While data are also publicly available for 267 PD
cases from the Fung et al. GWAS [18], that study only
included cases whose age of PD onset was 55 years or
greater resulting in an age distribution that was signifi-
cantly different from the other two samples (p < 0.0001).
Therefore, we did not include the cases from that study in
our meta-analysis due to limited variability in the onset
distribution.
Population stratification
Both the GenePD-PROGENI and Mayo-Perlegen LEAPS
sample sets were screened for population outliers during
initial QC. In addition, after the final study sample sets
were determined, principle components were recalculated
independently for each study using only the samples
included in the final analyses. Association to onset age
was then tested for the first six principle components for
each study. No association (p < 0.05) between the first six
principle components and onset age was seen in either
study sample.
Imputation
Imputation was performed to increase the power of the
meta-analysis and to facilitate the joint analysis of results
generated from Mayo-Perlegen LEAPS and our GWAS,
which were genotyped on different platforms. The pro-
gram MACH 1.0 (compiled using Intel's optimized com-
piler) was used to impute genotypes for 2,543,887
autosomal SNPs characterized in the HapMap project [30-
32].
The GenePD-PROGENI sample and the Mayo-Perlegen
LEAPS cohort were imputed separately using phased hap-
lotype data downloaded from the HapMap project web-
site [33].
In the GenePD-PROGENI sample, imputation was per-
formed using both cases and controls. A subset of 200
cases and controls with high call rates was selected to per-
form the initial model parameter calculation. Next, impu-
tation was performed on all participants using all
autosomal SNPs where the strand was not ambiguous (i.e.
not an A/T or G/C SNP) and that passed all other quality
control measures described previously. In the Mayo-Perle-
gen LEAPS cohort, all PD cases were used to compute the
initial model parameters. All unambiguous autosomal
SNPs passing quality review, as described in the original
Mayo-Perlegen LEAPS GWAS [19], were used for this
imputation. In addition, because the genotyping platform
used in the Mayo-Perlegen LEAPS study included a high
percentage of ambiguous SNPs, those ambiguous SNPs
which could be confidently matched to HapMap strands
through the comparison of minor allele frequencies were
also used for imputation. For each study, initial model
parameters were calculated using 100 iterations. SNP
quality was assessed using the Rsq metric, which estimates
the squared correlation between imputed and actual gen-
otypes with SNPs having an Rsq <0.3 excluded from fur-
ther study (N = 61,271).
At the time of this study, only autosomal imputation is
supported by MACH; therefore, the program IMPUTE was
used to impute SNPs on the X chromosome [34,35]http:/
/www.stats.ox.ac.uk/~marchini/software/gwas/
impute.html. Haplotype, legend, and recombination rate
files based upon HapMap (rel#21-NCBI build 35) were
downloaded from IMPUTE's website for use in imputing
64,621 SNPs in the non-pseudoautosomal region of the X
chromosome. Imputation was run in all participants in
the GenePD-PROGENI study and separately in all PD
cases in the Mayo-Perlegen LEAPS GWAS, using all X-
chromosome SNPs that passed quality assessment as
described above and were found in the legend file pro-
vided by IMPUTE.Page 3 of 14
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In order to meta-analyze results from both studies, associ-
ation to onset age was performed using exclusively
imputed, not genotyped data, for 1,861,750 SNPs passing
imputation QC and with minor allele frequencies greater
than 10%. Imputed SNPs with minor allele frequencies
less than 10% in the GenePD-PROGENI sample (N =
620,866) were excluded from the association analyses to
avoid false positives that can occur in the analysis of low
minor allele frequency SNPs. To evaluate SNP association
under an additive mode of inheritance, the predicted
allele dosage for each genotype estimated by MACH for
autosomes or by IMPUTE for the X chromosome was
used. To model the recessive and dominant modes of
inheritance, the genotype probabilities calculated by
MACH were used. While a combination of additive and
recessive models can have high power to detect dominant
effects, this power decreases as the minor allele frequency
of the SNP nears 0.5 [36]. Therefore, we studied additive,
dominant and recessive models. The total probability of
having either one copy or two copies of the minor allele
was used for the dominant model and the probability of
having two copies of the minor allele was used for the
recessive model. Recessive and dominant models were
not studied for the X chromosome. Linear regression anal-
yses were performed using SAS v9.1.
Meta-Analysis
Since the genotypic data was generated on different arrays
(Illumina and Perlegen) with few SNPs in common, we
employed a conservative meta-analytic approach to com-
bine results from the two studies. Meta-analysis of the
results of the linear regression of the imputed data for the
GenePD-PROGENI sample and the Mayo-Perlegen LEAPS
cohort was performed using METAL http://
www.sph.umich.edu/csg/abecasis/metal/. As is common
in GWAS meta-analyses, a fixed effects model with stand-
ard error weighting was used, as random-effects models
may be too conservative in GWA studies with a small
number of studies[37].
Replication Study
In order to validate the top findings from the GWAS meta-
analysis, an additional sample of 896 PD cases with
reported ages of PD onset was provided by the Parkinson
Institute - Istituti Clinici di Perfezionamento, Milan, Italy
from the "Human Genetic Bank of Patients Affected by PD
and Parkinsonisms". These cases were recruited irrespec-
tive of family history or onset age, and similar to the
GenePD-PROGENI, used the UK Parkinson's Disease
Society Brain Bank criteria to confirm idiopathic PD [38]
and defined onset as the age of first symptom of PD.
Twenty-four SNPs were selected based upon the following
criteria (1) a p-value less than 0.00001 in the meta-analy-
sis of the two GWAS, with (2) a consistent direction of
effect in both studies. Nine SNPs meeting these criteria
were identified from the additive inheritance model, thir-
teen from the dominant model and eleven from the reces-
sive model. Four SNPs were identified in both the additive
and dominant model, one SNP was identified in both the
additive and recessive model and one SNP was identified
by all three models. Three gene regions were identified
under two different genetic models with different SNPs.
For each multiply-nominated gene region, the SNP from
the model with the smaller p-value was selected for repli-
cation. These SNPs were genotyped using TaqMan tech-
nology implemented on the ABI PRISM® 7900HT
Sequence Detection system (Applied Biosystems: Foster
City, CA) at Boston University School of Medicine. Indi-
vidual samples (149) with genotyping call rates of less
than 95% were excluded from further analysis.
Association of the 24 SNPs to onset age was evaluated in
the 747 remaining Italian cases using linear regression
performed with the software Plink v1.01 http://
pngu.mgh.harvard.edu/purcell/plink/[39] using the cor-
responding genetic model (additive, recessive or domi-
nant) by which each SNP was originally identified. A final
fixed effects meta-analysis of all three studies was per-
formed using METAL.
To distinguish whether associations observed were to age
in general, as opposed to age at onset of PD, linear regres-
sion to censoring age was performed in the 867 NINDS
control samples genotyped with the GenePD-PROGENI
cases.
Results
Demographic characteristics of the three samples studied
are shown in Table 1. All three studies have a similar per-
centage of male participants. The GenePD-PROGENI and
Mayo-Perlegen LEAPS samples have similar mean ages of
PD onset, while the Italian sample has a somewhat
younger average age at onset. The GenePD-PROGENI
sample has the widest range of onset ages from 19 to 90
years while the Mayo-Perlegen LEAPS has no participants
under 30 years of age and the Italian sample has no par-
ticipants over 81 years of age. No significant differences in
onset age are seen between men and women in any of the
studies.
Supplementary Tables S1 (additive model), S2 (dominant
model) and S3 (recessive model) (see Additional file 1)
present the top SNPs from each region with a meta-analy-
sis p < 0.0001 for imputed SNP data in the GenePD-PRO-
GENI and Mayo-Perlegen LEAPS studies. Twenty-four
SNPs with meta-analysis p-values of less than 0.00001
and with a consistent direction of effect for both GWAS
were genotyped in the Italian replication sample of 747
PD cases (Table 2). SNPs genotyped in either the GenePD-
PROGENI or Mayo-Perlegen LEAPS GWAS platforms arePage 4 of 14
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both studies. The results of the association analysis in the
Italian sample, as well as the combined meta-analysis of
all three samples, are shown in Tables 3 (additive), 4
(dominant), and 5 (recessive) and in Figure 1.
Although ten of the replication SNPs showed a consistent
direction of effect across all three studies, only two SNPs
(both of which were genotyped on the Mayo-Perlegen
LEAPS GWAS platforms) resulted in increased statistical
evidence of association when combining the three studies,
and both of these were in a recessive model. The most
strongly associated SNP, rs10767971, located on chromo-
some 11 between the genes QSER1 and PRRG4, was asso-
ciated with a 3.2 year older PD onset in individuals with
2 copies of the minor allele (p = 5.4 × 10-7 in the 3 sample
meta-analysis, compared to 4.3 × 10-6 in the 2 sample
meta-analysis). Conversely, an estimated 6.9 year earlier
age of onset (p = 8.7 × 10-6 in the 3 sample meta-analysis
compared to 9.8 × 10-6 in the 2 sample meta-analysis)
was observed for the SNP rs7577851, located in the 16th
intron of the gene AAK1 on chromosome 2.
The most highly associated SNP in both the additive and
dominant three sample meta-analyses, rs17565841, is
located approximately 3 kb from the 3' end of the gene
OCA2 on chromosome 15. This SNP was associated with
an average 2.8 years younger onset age (p = 2.6 × 10-6)
under an additive model and a 3.3 years younger onset
age (p = 2.1 × 10-6) under a dominant model. Inclusion of
the Italian cases in the meta-analysis did not strengthen
the evidence of association as compared to the results seen
in the two sample meta-analyses (9.1 × 10-7 for additive
and 1.9 × 10-6 for dominant). However, in the Italian rep-
lication sample, this SNP did provide modest statistical
association to onset age (p = 0.05 for additive and p = 0.04
for dominant) with the same direction of effect seen in the
two other studies.
Also showing consistent directions of effect and p-values
in the three-sample meta-analysis at the level of p < 1 × 10-
5 were two SNPs located in the genes DSG3 and ATF6. The
SNP rs1941184, had the second best p-value identified
under the dominant model and is located in the third
intron of the gene DSG3 on chromosome 18. This SNP
was associated with an average 2.3 year younger age of
onset of PD across the three studies (p = 4.3 × 10-6). The
SNP rs10918270, located in the 15th intron of the gene
ATF6 on chromosome 1, was identified under both addi-
tive and dominant modes of inheritance, but showed
stronger association in the three sample meta-analysis
under the dominant model (p = 7.5 × 10-6) with an aver-
age 2.3 year younger onset of PD. No association to age
with direction of effect consistent with that observed for
onset age of PD was seen in the control sample for any of
the 24 SNPs at a significance level equal to 0.05.
Discussion
We present results from the first GWAS for age at onset of
PD, including a meta-analysis with the publicly available
Mayo-Perlegen LEAPS GWAS data (dbGaP Study Acces-
sion: phs000048.v1.p1) and a follow-up replication study
in an independent PD sample recruited in Milan, Italy.
Differences were observed in the age distributions in the
three populations used in this study (Table 1). However,
there were no imposed age restrictions in any of the stud-
ies and a wide distribution of ages was represented in all
three populations, each with a range of greater than 60
years.
No SNP reached the commonly accepted criterion for
genome-wide significance of p < 5 × 10-8 [40], which is
based on recent estimates of independent genomewide
sequence variation to maintain 5% genomewide type I
error rate [41,42]. While this criterion provides an appro-
priate cutoff for determining significance for the large
number of SNPs provided by imputation, this measure
does not account for the testing of multiple genetic mod-
els, as was performed in this study. Despite the lack of
genomewide significance, the meta-analysis in this study
showed evidence of several interesting loci with consistent
effects on onset age of PD across the three independent
populations studied.
The SNP with the strongest evidence for association to
onset age, rs10767971, is associated with a later age of
onset under a recessive model. This SNP is nearly equidis-
tant between the genes PRRG4 and QSER1 on chromo-
some 11, at just under 20 kb from each. The association
results for nearby SNPs studied in the meta-analysis of the
two GWAS as well as the LD structure and recombination
rates for the region are shown in Figure 2A and 2B under
Table 1: Age and sex distribution of the GenePD- PROGENI, Mayo-Perlegen LEAPS, and Milan, Italian study samples.
N % Male Mean Onset Std Dev Onset Range Onset
GenePD-PROGENI 857 59.2 61.9 10.9 19-90
Mayo-Perlegen LEAPS 440 61.6 61.0 11.2 30-94
Milan, Italian 747 59.4 55.2 10.8 20-81Page 5 of 14
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dence of association appeared with a recessive model,
many nearby SNPs in strong LD showed similar associa-
tion under the dominant model. The pattern suggests a
single association, spanning several SNPs that may be
more evident around the PRRG4 gene and may extend
toward the CCDC73 and EIF3M genes.
The SNP showing the strongest association to PD onset
across the three populations under both the additive and
dominant models lies 3 kb from the 3' end of the gene
OCA2 (oculocutaneous albinism II). Mutations in OCA2
are responsible for the most common form of albinism,
oculocutaneous albinism type 2 [43] and several studies
have shown this gene to be associated with common skin,
hair and eye color variation found in European popula-
Table 2: Location and minor allele frequency (MAF) information for 24 SNPs selected for replication study in Italian sample
Chr SNP SNP positiona Minor Allele MAF Genes in Regionb
1 rs7556447 2,335,959 G 0.24 PEX10
1 rs1355637c 148,849,062 T 0.19 MCL1|ENSA
1 rs10918270 160,182,125 A 0.41 ATF6
2 rs11899121 20,231,454 C 0.50 SDC1
2 rs7577851c 69,577,214 T 0.17 AAK1
2 rs17817190 134,068,118 G 0.11 NAP5
6 rs6936388 42,275,464 T 0.25 CCND3|TAF8|GUCA1A|GUCA1B|MRPS10
6 rs1572662 154,853,289 A 0.36 CNKSR3|CLDN20|RBM16|TIAM2|TFB1M
7 rs1420143c 29,514,849 C 0.44 CHN2
7 rs17663983 76,243,177 T 0.12
10 rs12261736 52,738,610 T 0.28 PRKG1
10 rs7076519 127,738,829 C 0.33 ADAM12
11 rs10767971c 32,852,240 T 0.42 PRRG4|QSER1
12 rs12829697 30,067,223 G 0.13
12 rs10773917 130,572,784 T 0.23
13 rs4771006d 26,180,684 A 0.49 WASF3
13 rs676495c 29,561,754 T 0.24
14 rs10147486 47,054,769 T 0.27 MDGA2
15 rs17565841 25,670,842 A 0.10 OCA2
17 rs9904572 12,803,084 A 0.34 RICH2
17 rs4791571c 14,155,801 A 0.42 HS3ST3B1
18 rs1941184 27,292,121 C 0.30 DSG3
19 rs10420134 40,953,768 G 0.18 C19orf55|SNX26
20 rs3887942 23,925,072 G 0.19 GGTLC1
a From NCBI Build 36 reference; b Nearest genes within 100 kb of SNP;c SNP was genotyped in Mayo-Perlegen LEAPS GWAS;d SNP was genotyped 
in GenePD-PROGENI GWASPage 6 of 14
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with susceptibility to melanoma [49], which has also
been reported to occur with increased frequency among
PD cases [50-52]. Because of the targeted degradation of
pigmented neurons in PD brains, these associations have
lead to a hypothesized link between genes involved in pig-
mentation, such as OCA2, and PD, likely mediated
through common elements in melanin and neuromela-
nin synthesis[53]. The protein encoded by OCA2, 'P' pro-
tein, is involved in the transport of tyrosine, a precursor to
melanin, as well as in the regulation of melanosomal pH
which may be key to the initiation of the enzyme control-
ling melanin synthesis in melanocytes [54]. It is not clear
whether synthesis of neuromelanin is also regulated
Table 3: Additive model study-specific and meta-analysis results
GenePD-PROGENI Mayo-Perlegen 
LEAPS
GWAS Meta-analysis Milan, Italian Three Sample Meta-analysis
SNP effect p-value effect p-value Direction 
of Effect
effect p-value effect p-value Direction 
of Effect
effect p-value
rs17565841 -4.66 2.7 × 10-6 -3.64 1.7 × 10-1 -- -4.53 9.1 × 10-7 -1.57 5.0 × 10-2 --- -2.84 2.6 × 10-6
rs10918270 -2.12 1.1 × 10-4 -1.90 1.6 × 10-2 -- -2.05 4.8 × 10-6 -0.62 2.7 × 10-1 --- -1.49 2.0 × 10-5
rs12261736 -3.61 1.8 × 10-7 -1.17 4.0 × 10-1 -- -3.13 3.5 × 10-7 -0.42 4.5 × 10-1 --- -1.65 6.6 × 10-5
rs4771006 2.35 1.6 × 10-3 2.59 1.6 × 10-3 ++ 2.46 7.3 × 10-6 0.50 3.8 × 10-1 +++ 1.52 1.2 × 10-4
rs1420143 2.08 1.4 × 10-4 2.58 8.1 × 10-3 ++ 2.20 3.6 × 10-6 0.02 9.8 × 10-1 +++ 1.27 4.1 × 10-4
rs6936388 2.45 4.2 × 10-4 2.98 7.2 × 10-3 ++ 2.60 9.2 × 10-6 -0.31 7.0 × 10-1 ++- 1.58 8.2 × 10-4
rs10147486 2.21 3.1 × 10-4 2.89 8.0 × 10-4 ++ 2.44 9.2 × 10-7 -0.69 3.0 × 10-1 ++- 1.31 9.5 × 10-4
rs7076519 -2.71 9.3 × 10-6 -2.53 2.5 × 10-2 -- -2.67 6.0 × 10-7 0.68 1.8 × 10-1 --+ -0.92 1.3 × 10-2
Table 4: Dominant model study-specific and meta-analysis results
GenePD-PROGENI Mayo-Perlegen 
LEAPS
GWAS Meta-analysis Milan, Italian Three Sample Meta-analysis
SNP effect p-value effect p-value Direction 
of Effect
effect p-value effect p-value Direction 
of Effect
effect p-value
rs17565841 -5.08 4.7 × 10-6 -3.68 2.0 × 10-1 -- -4.90 1.9 × 10-6 -1.94 3.6 × 10-2 --- -3.26 2.1 × 10-6
rs1941184 -2.94 1.3 × 10-4 -2.94 1.0 × 10-2 -- -2.94 3.7 × 10-6 -1.25 1.2 × 10-1 --- -2.28 4.3 × 10-6
rs10918270 -3.26 2.9 × 10-5 -2.74 1.5 × 10-2 -- -3.09 1.2 × 10-6 -0.87 2.9 × 10-1 --- -2.26 7.5 × 10-6
rs3887942 4.17 7.2 × 10-4 7.10 1.5 × 10-3 ++ 4.85 6.4 × 10-6 0.93 2.6 × 10-1 +++ 2.37 2.7 × 10-4
rs12261736 -4.03 9.5 × 10-6 -2.04 2.8 × 10-1 -- -3.66 7.3 × 10-6 -0.46 5.7 × 10-1 --- -2.07 3.5 × 10-4
rs10773917 3.15 3.8 × 10-5 2.58 3.5 × 10-2 ++ 2.99 3.7 × 10-6 -0.13 8.7 × 10-1 ++- 1.75 4.8 × 10-4
rs10420134 -3.21 5.8 × 10-5 -3.12 5.1 × 10-2 -- -3.19 7.1 × 10-6 0.56 5.1 × 10-1 --+ -1.67 2.3 × 10-3
rs9904572 3.57 4.3 × 10-6 2.72 6.4 × 10-2 ++ 3.38 7.2 × 10-7 -1.05 1.9 × 10-1 ++- 1.55 3.1 × 10-3
rs17817190 -3.87 3.9 × 10-5 -5.27 2.1 × 10-2 -- -4.07 2.5 × 10-6 1.30 2.1 × 10-1 --+ -1.85 5.3 × 10-3
rs1572662 3.57 4.1 × 10-5 4.89 7.5 × 10-2 ++ 3.69 7.8 × 10-6 -0.67 4.1 × 10-1 ++- 1.45 1.2 × 10-2
rs7076519 -3.73 1.2 × 10-5 -3.81 3.0 × 10-2 -- -3.74 9.3 × 10-7 1.48 6.2 × 10-2 --+ -1.23 2.6 × 10-2Page 7 of 14
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in a similar way [55]. Nevertheless, the association
between OCA2 and younger age of onset are suggestive of
a neuromelanin-related mechanism of effect.
The association of an intronic SNP in the gene DSG3 (des-
moglein 3 (pemphigus vulgaris antigen)) may also be
indicative of a neuromelanin related effect on onset age of
PD. The protein encoded by DSG3 is the autoantigen for
the autoimmune skin disease pemphigus vulgaris and this
gene is expressed primarily in skin. Interestingly, some
reports have demonstrated increased expression of DSG3
in melanocytes compared to keratinocytes (the most com-
mon cell type in the epidermis) [56].
An intronic SNP in the gene ATF6 also showed strong
association to earlier age of onset of PD. ATF6 (activating
transcription factor 6) transcribes a transcription factor
localized to the endoplasmic reticulum (ER). The ATF6
protein is a critical regulator of the unfolded protein
response (UPR), a highly conserved pathway activated in
response to ER stress, and is a protective cellular response
to the accumulation of misfolded proteins [57-59]. The
UPR has been implicated in neurotoxin based cellular
models of PD [60] and has also been shown to be acti-
vated by the over-expression of α-synuclein in yeast cells
[61]. More recently, postmortem studies of PD case and
control brains have shown activation of the UPR in cases,
but not controls and that this activation is associated with
the aggregation of α-synuclein [62].
The finding of an intronic SNP in AAK1 associated with
PD onset age is intriguing because of the gene's genomic
location, its function, and its close relation to a gene iden-
tified for PD susceptibility. The AAK1 (AP2 associated
kinase 1) gene is located on chromosome 2p14, near
2p13, which has previously been implicated as the PARK3
locus[63], and for which linkage to onset age was demon-
strated in both the GenePD [64] and PROGENI [65] stud-
ies. The AAK1 gene itself has not been previously
implicated by positional mapping, but a microarray study
of PD brain compared to controls demonstrated differen-
tial expression of AAK1 [66]. In our past GWAS of PD sus-
ceptibility in the GenePD-PROGENI cohort [20], the
region containing the gene GAK (cyclin G-associated
kinase) had the strongest evidence for association (chro-
mosome 4p). The AAK1 and GAK genes both function at
multiple steps in clathrin-mediated vesicular transport
and the two kinases likely have some redundant functions
[67] related to their homologous serine/threonine-kinase
domain [68]. Recently, cathepsin D was implicated as the
main lysosomal enzyme involved in α-synuclein degreda-
tion [69], and depletion of GAK was shown to impair the
lysosomal sorting of cathepsin D [68]. Thus, the finding
Table 5: Recessive model study-specific and meta-analysis results
GenePD-PROGENI Mayo-Perlegen 
LEAPS
GWAS Meta-analysis Milan, Italian Three Sample Meta-analysis
SNP effect p-value effect p-value Direction 
of Effect
effect p-value effect p-value Direction 
of Effect
effect p-value
rs10767971 4.23 9.3 × 10-6 2.35 1.3 × 10-1 ++ 3.71 4.3 × 10-6 2.40 2.6 × 10-2 +++ 3.24 5.4 × 10-7
rs7577851 -8.64 1.2 × 10-4 -8.03 3.1 × 10-2 -- -8.48 9.8 × 10-6 -3.89 1.3 × 10-1 --- -6.85 8.7 × 10-6
rs1355637 -5.10 2.3 × 10-3 -14.25 4.1 × 10-5 -- -6.83 5.1 × 10-6 1.10 6.0 × 10-1 --+ -4.19 6.2 × 10-4
rs11899121 -3.41 8.0 × 10-5 -3.33 1.6 × 10-2 -- -3.39 3.5 × 10-6 0.43 6.5 × 10-1 --+ -1.99 6.3 × 10-4
rs12829697 -10.51 8.5 × 10-5 -10.33 3.0 × 10-2 -- -10.47 7.0 × 10-6 0.68 8.1 × 10-1 --+ -6.15 7.2 × 10-4
rs17663983 -16.72 1.2 × 10-5 -25.53 4.6 × 10-1 -- -16.83 8.1 × 10-6 5.77 2.9 × 10-1 --+ -9.46 2.3 × 10-3
rs12261736 -8.48 1.9 × 10-6 -0.56 8.9 × 10-1 -- -7.14 9.6 × 10-6 -0.73 4.9 × 10-1 --- -2.65 2.7 × 10-3
rs1420143 3.31 7.9 × 10-4 6.05 1.3 × 10-3 ++ 3.90 7.3 × 10-6 -0.52 5.9 × 10-1 ++- 1.89 3.3 × 10-3
rs676495 -6.90 1.9 × 10-5 -11.27 2.4 × 10-1 -- -7.02 9.1 × 10-6 1.86 2.7 × 10-1 --+ -2.84 1.4 × 10-2
rs7556447 -13.34 2.1 × 10-5 -11.11 1.9 × 10-1 -- -13.08 7.9 × 10-6 -0.44 7.7 × 10-1 --- -3.01 2.3 × 10-2
rs4791571 -5.18 1.3 × 10-5 -6.39 2.4 × 10-1 -- -5.23 5.9 × 10-6 2.57 3.5 × 10-2 --+ -1.52 6.9 × 10-2Page 8 of 14
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familial PD suggest that pathways involving lysosomal
activity influence PD risk.
Several previous genome scans have provided evidence of
loci linked to onset age, including 2p13 seen in both the
GenePD and PROGENI studies, as mentioned above. Evi-
dence of linkage has also been reported on chromosomes
1p, 1q, 8q, 9q, 10q, 20 and 21[64,65,70], but there is little
overlap between these linkage regions and our top meta-
analysis association results. Aside from the identification
of the AAK1 gene near 2p13, the strongest association
result observed under one of the previously reported link-
age regions occurs near the gene sortilin-related VPS10
domain containing receptor 3 (SORCS3) located near the
LOD score peak at 10q, originally identified in a com-
bined linkage scan of onset age in PD and Alzheimer's dis-
ease [70]. This association is seen most strongly under a
dominant model (p = 2.5 × 10-5) with minor allele carriers
having an estimated older onset age by 3.3 years (see
Additional file 1: Table S2).
A final region of interest is 15q26.2 that includes the gene
MCTP2. Several SNPs in this region showed association to
earlier onset age of PD in the meta-analysis of the two
GWAS under the recessive model (see Additional file 1:
Table S3). These SNPs did not reach the criteria for inclu-
sion in the replication study, as the strongest p-value seen
was 2.2 × 10-5 with rs17504636. This SNP was associated
with a 9.2 year earlier average PD onset. This region over-
laps with a SNP reported in the susceptibility GWAS
including these cases [20]. In that study the SNP
rs4476132 was associated with PD susceptibility with an
odds ratio of 1.3 (p = 7.7 × 10-5- meta-analysis with addi-
tive model). This overlap is consistent with a locus associ-
ated with a risk for younger-onset PD or with an effect
modifying age dependent penetrance. The gene in this
region, MCTP2 (multiple C2 domains, transmembrane
2), is expressed in the brain and has been implicated in
linkage and association studies of abdominal fat [71] and
major depression [72].
Important distinctions can be made between those genes
that influence susceptibility for developing disease, and the
genetic modifiers that influence penetrance or, as studied
here, onset age. Perhaps the best examples for genetic modi-
fiers are seen for Huntington's disease (HD) where an
expanded CAG trinucleotide repeat on chromosome 4p16.3
Forest plots showing study-specific and pooled effects for top six results in final meta-analysisigure 1
Forest plots showing study-specific and pooled effects for top six results in final meta-analysis. The effect (in 
years) on age at PD onset and 95% confidence intervals for the indicated genetic model are shown for each of the three inde-
pendent samples and the combined analysis. A. Additive model of the A allele in SNP rs17565841 B. Dominant model of the A 
allele in SNP rs17565841 C. Dominant model of the C allele in SNP rs1941184 D. Dominant model of the A allele in SNP 
rs10918270 E. Recessive model of the T allele in SNP rs10767971 F. Recessive model of the T allele in SNP rs7577851.Page 9 of 14
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for individuals with identical repeat lengths. The identifica-
tion of the genes that presumably interact with huntingtin to
produce relatively younger or older onset for a given repeat
size provide insight into the pathogenic mechanisms for HD,
as well as therapeutic targets for intervention [73-75]. Simi-
larly, identifying those genes and their products that are asso-
ciated with older onset in PD may provide insight into the
disease mechanisms and processes for delaying onset with
implications for novel treatments.
Conclusion
The identification of the 15q26.2 region as well as the
related genes AAK1 and GAK in the studies of PD onset
age and susceptibility highlights the importance of the
continued study of both of these traits, both separately
and in combination. The direct overlap in affection and
onset age association results in the 15q26.2 region shows
this to be a candidate region that would benefit from fur-
ther examination with consideration of important age-
related effects, for example in studies correlating expres-
sion of genes in this region with onset age. The identifica-
tion of association to onset age with the gene AAK1, in the
same pathway as a previously identified susceptibility-
associated gene GAK highlights the importance of genetic
pathways in PD etiology, showing that the genes along the
same pathway may have redundant effects or may modify
disease pathology different ways, observed by differences
in disease onset and progression. Studying PD in the con-
text of onset age provides fundamental insight into the
disease process and is essential to understanding mecha-
nisms that modify disease penetrance and therefore may
be key in identifying therapeutic targets.
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Evidence of association in Chromosome 11 regionFigure 2
Evidence of association in Chromosome 11 region. Along the x axis is the physical position in the region (in kB) with 
known genes shown in their orientation The left Y-axis denotes the association test result as -log(p-value) corresponding to 
diamonds in the figure. The blue diamond identifies the primary SNP result labeled with an rs# and p-value. The color of addi-
tional diamonds depicts the pairwise linkage disequilibrium with the primary SNP: red indicates r2 > 0.8, orange 0.5 < r2 < 0.8, 
yellow 0.2 < r2 < 0.5, white r2 < 0.2, grey unknown LD. R2 values were obtained from the CEPH HapMap data. The right Y-axis 
indicates the recombination rate, also obtained from CEPH HapMap data, and shown within the figure by the solid light-blue 
line. A. Recessive model B. Dominant model.Page 10 of 14
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